Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 329, 31-40
Abstract
No abstract availableKeywords
Funding Information
- National Science Fund Projects of China (81672997, 81703047)
- Shanghai Science and Technology Development Funds (18431903900)
- National Key Research and Development Program on Precision Medicine of China (2017YFC0909800)
This publication has 40 references indexed in Scilit:
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in MiceGastroenterology, 2012
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric ReceptorMolecular Therapy, 2012
- Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal AdenocarcinomaPancreas, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences, 2009
- A Binding Domain on Mesothelin for CA125/MUC16Journal of Biological Chemistry, 2009
- MesothelinClinical Cancer Research, 2004
- Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell AdhesionJournal of Biological Chemistry, 2004